Given that stem cell infusion from donors can treat persistent pancytopenia after CD19 CAR-T cells therapy with minimal side effects, 2 patients with poor baseline conditions received donor-derived stem cells after CLL-1 CAR-T cells. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.